(Q53249660)

12 May 2018

title

Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer. (English)

1 reference

12 May 2018

main subject

phase II clinical trial

0 references

phase I clinical trial

0 references

1 reference

5

A Schneeweiss

1 reference

12 May 2018

N Frickhofen

1

1 reference

12 May 2018

W E Berdel

2

1 reference

12 May 2018

F Opri

3

1 reference

12 May 2018

R Haas

4

1 reference

12 May 2018

M Sandherr

6

1 reference

12 May 2018

W Kuhn

7

1 reference

12 May 2018

D K Hossfeld

8

1 reference

12 May 2018

C Thomssen

9

1 reference

12 May 2018

H Heimpel

10

1 reference

12 May 2018

R Kreienberg

11

1 reference

12 May 2018

A Hinke

12

1 reference

12 May 2018

V Möbus

13

1 reference

12 May 2018

German Study Groups Arbeitsgemeinschaft Internistische Onkologie (AIO)

14

1 reference

12 May 2018

Arbeitsgemeinschaft Gynäkologische Onkologie (AGO)

15

1 reference

12 May 2018

language of work or name

English

0 references

publication date

21 August 2006

1 reference

12 May 2018

Bone Marrow Transplantation

published in

1 reference

12 May 2018

volume

38

1 reference

12 May 2018

issue

7

1 reference

12 May 2018

page(s)

493-499

1 reference

12 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705472

exact match

0 references

cites work

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

A systematic overview of chemotherapy effects in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: long term results for 105 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

Some practical improvements in the continual reassessment method for phase I studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

7 January 2021

High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

7 January 2021

High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

7 January 2021

Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

7 January 2021

Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705472

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705472

1 reference

12 May 2018

1 reference

12 May 2018